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Abstract: Exposure to polyunsaturated fatty acids (PUFA) influences immune function and may
affect the risk of allergy development. Long chain PUFAs are produced from dietary precursors
catalyzed by desaturases and elongases encoded by FADS and ELOVL genes. In 211 subjects,
we investigated whether polymorphisms in the FADS gene cluster and the ELOVL2 gene were
associated with allergy or PUFA composition in serum phospholipids in a Swedish birth-cohort
sampled at birth and at 13 years of age; allergy was diagnosed at 13 years of age. Minor allele
carriers of rs102275 and rs174448 (FADS gene cluster) had decreased proportions of 20:4 n-6 in cord
and adolescent serum and increased proportions of 20:3 n-6 in cord serum as well as a nominally
reduced risk of developing atopic eczema, but not respiratory allergy, at 13 years of age. Minor
allele carriers of rs17606561 in the ELOVL2 gene had nominally decreased proportions of 20:4 n-6 in
cord serum but ELOVL polymorphisms (rs2236212 and rs17606561) were not associated with allergy
development. Thus, reduced capacity to desaturase n-6 PUFAs due to FADS polymorphisms was
nominally associated with reduced risk for eczema development, which could indicate a pathogenic
role for long-chain PUFAs in allergy development.
Keywords: long chain polyunsaturated fatty acids; arachidonic acid; phospholipids; umbilical
cord serum; single nucleotide polymorphism; fatty acid desaturase; FADS; elongase; ELOVL2;
nutrigenetics; allergy; atopic eczema; respiratory allergy; BAS birth cohort
1. Introduction
Polyunsaturated fatty acids (PUFAs) are essential for cell and tissue development and a sufficient
supply of PUFA is important from fetal life onwards. The fetus is mainly supplied with PUFAs by
transfer from the maternal circulation via the placenta [1]. After birth, PUFAs are available via the
diet, including breast milk or formula in infants and from fatty foods later in life. Important long
chain PUFAs, such as arachidonic acid and docosahexaenoic acid (DHA) may also be produced
in the body from their essential precursor fatty acids linoleic acid (18:2 n-6) and α-linolenic acid
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(18:3 n-3) that are abundant in the diet [2]. Substrate fatty acids are elongated by sequential addition
of two-carbon atom units and desaturated by introduction of a double bond in the molecule. The
elongation step is catalyzed by elongases encoded by the ELOVL (elongation of very long chain
fatty acids) gene family on chromosome 6 [3], while desaturation is catalyzed by desaturases such
as ∆-5 and ∆-6 desaturases, encoded by the FADS (fatty acid desaturase) gene cluster on chromosome
11 [4–6] (Figure 1). The production of longer n-6 and longer n-3 PUFAs involves the same enzymes
(elongases and desaturases), hence, there is a competition for the enzymes between the two pathways
(Figure 1). Desaturation is the rate limiting step in this pathway and several studies have revealed
that single nucleotide polymorphism (SNPs) in the FADS gene cluster affect the proportions of PUFA
and long chain PUFA in human tissue [7–23]. Polymorphism in the FADS2 gene that negatively affect
the activity of the ∆-6 desaturase, have been associated with increased proportions of linoleic acid
(precursor for the n-6 series) and α-linolenic acid (precursor for the n-3 series), while the products
arachidonic acid (n-6) and eicosapentaenoic acid (EPA, n-3) are reduced. Recent genome-wide
association studies have also suggested that polymorphism in the ELOVL2 gene are associated with
increased proportions of the substrate and decreased proportions of the products [23–25].
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promote maturation of dendritic cells  into a phenotype that favors Th2  lineage commitment from 
naïve T cells with which  the dendritic cell  interacts. Th2 cells are central  in atopic  (IgE‐mediated) 
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Figure 1. The metabolic pathways of polyunsaturated fatty acids in mammals [26]. Fatty acids and
genes in bold were examined in this study.
PUFAs are important modulators of immune function. Long chain PUFAs are powerful
inhibitors of mitogen-induced activation [27–29] and secretion of interferon-γ by T cells [30,31].
Furthermore, the long chain n-6 PUFA arachidonic acid is the precursor of prostaglandins [32] that
promote maturation of dendritic cells into a phenotype that favors Th2 lineage commitment from
naïve T cells with which the dendritic cell interacts. Th2 cells are central in atopic (IgE-mediated)
allergy. We have recently shown that the risk of developing allergy is positively related to a high
proportion of both n-6 and n-3 long chain PUFAs in cord blood [33]. Since variation in the FADS
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genes affects serum proportions of long chain PUFAs [24,25,34] we speculated that genetic variation
in the FADS genes may also affect the risk of allergy development. Indeed, a German study found
that carriers of the minor alleles of several SNPs in FADS and their respective haplotypes had a lower
prevalence of allergic rhinitis and atopic eczema [13]. The effect of ELOVL polymorphisms on risk of
allergy development has not previously been studied.
The aim of the present study was to evaluate if genetic variations in the FADS gene cluster or in
the ELOVL2 gene were associated with proportions of long chain PUFAs in cord serum phospholipids
or in adolescents’ serum phospholipids, and to examine any potential association between genetic
variation and allergic disease at 13 years of age.
2. Experimental Section
2.1. Subjects
The birth-cohort consisted of all children (N = 1228) born during one year between February 1996
and January 1997 at Östersund Hospital in the County of Jämtland in Northern Sweden. The cohort
was designed to assess the development of allergy and the children underwent skin prick tests at
one and four years of age to detect sensitization to common food and airborne allergens. Also, their
parents responded to questionnaires regarding the children’s allergic symptoms at one, four, and
seven years of age. Socioeconomic, housing, and lifestyle factors were recorded by questionnaires.
As previously described [35,36], adolescents still participating in the study at 13 years of age (n = 841)
were invited to fill out a questionnaire regarding allergy symptoms, and other environmental factors
known to influence allergy, take part in skin prick tests, and donate a blood sample for PUFA analysis.
Seven hundred and eighty eight of the 841 adolescents took part in both skin prick test and answered
the questionnaire at the follow up at 13 years of age.
2.2. Allergy Diagnosis
Based on the questionnaires and sensitization tests at 13 years of age, the subjects were
divided into three diagnostic groups: (1) atopic eczema with no other allergic manifestations, in all,
79 adolescents out of the 788 fulfilled these criteria; (2) respiratory allergy with no other allergic
manifestations, all of whom were also sensitized to airborne allergens, in all, 130 adolescents in the
cohort fulfilled these criteria and (3) no allergy and no sensitization at any of the follow-ups (1, 4, 7
and 13 years of age), in all, 331 adolescents in the cohort fulfilled these criteria. Atopic eczema was
defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical features
and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka [37]. Respiratory
allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or
more of the following criteria: wheeze in the past year, doctor’s diagnosed asthma, asthma inhalation
treatment, or a positive answer to the question: “Have you had any signs of pollen allergy or allergy
to furry pets during the last 12 months?”.
2.3. Collection of Serum
Cord blood samples, a mixture of arterial and venous blood, were obtained at delivery from 819
of the children born vaginally. Serum was separated, aliquoted, and stored frozen until analyzed.
At 13 years of age, a subgroup of 300 adolescents was invited to take part in a new blood sampling.
Two hundred and seventy two adolescents gave blood on three different occasions: November 2009
(n = 88), April 2010 (n = 52) and January 2011 (n = 132). Venous blood, 10 mL, was drawn at any
time of the day, fasting was not required. The blood was allowed to clot. Serum was separated by
centrifugation, aliquoted and frozen within 3 h. It was stored at ´80 ˝C until analyzed.
10102
Nutrients 2015, 7, 10100–10115
Table 1. Characteristics of the birth cohort and the study population.
Selected Subjects 2
All
Subjects 1
Selected
Subjects 2
No
Allergy 3
Atopic
Eczema 4
Respiratory
Allergy 5
n = 841 n = 211 n = 88 n = 41 n = 82
Antenatal characteristics
Heridity
Maternal, % 43 45 36 51 52
Paternal, % 36 40 31 37 51
Maternal age at delivery 6, years old 29 (15–45) 29 (19–43) 29 (19–42) 29 (21–43) 29 (21–43)
Siblings 6, % 60 60 59 62 61
Birth characteristics
Gestational age at delivery 6, weeks 40 (30–43) 40 (34–43)
39.6
(35–43) 39.8 (34–43) 40.0 (35–42)
Birth weight 6, g
3573
(1386–5400)
3632
(2485–5400)
3606
(2485–5320)
3580
(2575–4300)
3685
(2588–5400)
Infant characteristic
Male gender, % 50 47 43 29 60
Exclusive breastfeeding at 4 months, % 72 72 74 77 68
Adolescent characteristics
BMI 19 (14–33) 19 (14–29) 20 (15–27) 19 (15–25) 19 (14–29)
Sensitized 32 41 0 10 100
Data are presented as % or mean (range). 1 All subjects that were invited to take part in the follow up at 13 years
of age; 2 Subjects that were selected for blood sampling at 13 years of age and approved participation in genetic
analyses; 3 No allergy and no sensitization at any of the follow-ups (1, 4, 7, and 13 years of age); 4 Atopic
eczema was defined as a pruritic, chronic, or chronically relapsing non-infectious dermatitis with typical
features and distribution, fulfilling three of the main criteria suggested by Hanifin and Rajka 6; 5 Respiratory
allergy was defined as a positive skin prick test to an inhalant allergen, in combination with two or more of
the following criteria: wheeze in the past year, doctor’s diagnosed asthma, asthma inhalation treatment, or
a positive answer to the question: “Have you had any signs of pollen allergy or allergy to furry pets during
the last 12 months?”; 6 Data obtained from the Swedish Medical Birth Register kept by The Swedish National
Board of Health and Welfare (Stockholm, Sweden).
2.4. Selection of Subjects
Out of the 272 subjects that agreed to give a blood sample at 13 years of age, 261 subjects gave
blood for genetic analysis. From these, 211 subjects were selected for analysis of genetic polymorphisms,
based on availability of cord serum. Forty one of these subjects had atopic eczema, 82 had respiratory
allergy, and 88 were non-allergic and non-sensitized.
2.5. Analysis of Fatty Acids in Serum Phospholipids
Briefly, 200 µL of serum was thawed in room temperature, vortexed and mixed with
chloroform:methanol (1:2) and 0.5% NaCl-solution [38]. Phospholipids were obtained by separation
on aminopropyl solid phase extraction columns (Isolute NH2, 6 mL, 500 mg, IST, Mid Glamorgon,
Cardiff, UK) [39] and converted to fatty acid methyl esters using acetyl chloride (10%) dissolved in
methanol [40] during overnight incubation in room temperature. The fatty acid methyl esters were
then extracted with 2 mL of petroleum ether. After evaporation under N2 in a 40 ˝C water bath the
samples were re-dissolved in 200 µL isooctane and fatty acid methyl esters were separated by gas
chromatography (Hewlett Packard 5890, Agilent Technology., Waldbronn, Germany). Detection was
done by flame ionization and the Borwin software ((JMBS Developpements, Le Fontanil, France) was
used for evaluation. The fatty acids were separated by gas chromatography on two different columns.
The samples were first separated on an HP Ultra 1 (50 m ˆ 0.32 mm ˆ 0.52 µm df silicon column
(J & W Scientific, Folsom, CA, USA) suitable for separation of the 20–22 carbon atom-long fatty
acids. Where sufficient materials remained in the vial after the first GC-run, we also performed
separation of 16–18 carbon atom-long fatty acids on a DB-WAX (30 mˆ 0.25 mmˆ 0.25 µm df ) column
(J & W Scientific, Folsom, CA, USA). Fatty acids that were found above the limit of quantification and
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could clearly be separated were selected for statistical analyses. The proportion of each fatty acid was
expressed as area percentage of the total fatty acids, i.e., all fatty acids 16–22 carbon atoms long.
2.6. Genetic Analyses
Genomic DNA was extracted from venous blood collected in EDTA tubes from the subjects at
13 years of age (n = 211). The standard protocol at Kbioscienses (LGC genomics, Hoddesdon, UK)
was used. SNP genotyping in the present study was guided by previous genome-wide association
studies showing significant association between fatty acids in serum phospholipids and SNPs in the
FADS gene cluster or the ELOVL gene family [24,25]. A total of six SNPs had been identified in
the FADS gene cluster (rs102275, rs174547, rs174550, rs1535, rs174574, rs14448) and a total of four
SNPs had been identified in the ELOVL gene family (rs17606561, rs3798713, rs3734398, rs2236212, all
situated in the ELOVL2 gene) [24,25]. For the six identified SNPs in the FADS gene cluster rs102275
was in complete linkage disequilibrium (LD, r2 = 1) with rs1535, rs174574, rs174547, and rs174550,
but not with rs174448 and hence only rs102275 and rs174448 were genotyped. For the four SNPs
in the ELOVL2 gene rs2236212 was in complete LD with rs3798713 (r2 = 1) and in almost complete
LD with rs3734398 (r2 = 0.966), therefore only rs2236212 and rs17606561 were genotyped from these
four identified SNPs. This led to two SNPs in the FADS gene cluster (rs102275 and rs174448) and
two SNPs in the ELOVL2 gene (rs2236212 and rs17606561) being selected for genotyping (Figure 2).
Characteristics of the analyzed SNPs are shown in Table 2.
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Figure 2. Overview of the FADS gene cluster (in top) and the ELOVL2 gene (below) and the SNPs 
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Figure 2. Overview of the FADS gene cluster (in top) and the ELOVL2 gene (below) and the SNPs
analyzed in this study. Position was derived from UCSC Genome Browser on Human December 2013
(GRCh38/hg38) Assembly.
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Table 2. Characteristics of single nucleotide polymorphisms in the ELOVL2 gene and the FADS
gene cluster.
SNP Function Chromosome Position
1
(bp)
Major > Minor Minor AlleleFrequency 2
ELOVL2 gene
rs17606561 3 prime UTR variant 6 10 982 126 G > A 0.182
rs2236212 Intron variant 6 10 994 782 G > C 0.487
FADS gene cluster
rs102275 Intergenic 11 61 790 331 T > C 0.493
rs174448 Intergenic 11 61 872 101 A > G 0.404
1 Position in base pairs was derived from UCSC Genome Browser on Human December 2013 (GRCh38/hg38)
Assembly; 2 Minor allele frequency is taken from the current default global population is 1000Genome phase
1 genotype data from 1094 worldwide individuals, released in the May 2011 dataset.
2.7. Statistics
Hardy-Weinberg equilibrium was investigated with a chi-square goodness of fit. SNPs were
analyzed coded according to minor allele count (0, 1, 2) and analyzed as a numeric variable.
The association between SNPs and fatty acids was analyzed using linear regression and the
association between SNPs and allergy was analyzed with logistic regression both univariable and
in a multivariable setting with a risk associated fatty acid as the other predictor. Haplotypes were
constructed using the EM-algorithm and haplotype counts used as predictors. Correction for multiple
testing was carried out by permutation [41] to take into account the correlations between outcomes
as well as SNPs. For each gene separately and for three separate outcome groups—15 phospholipid
variables in cord serum and in adolescent serum and also for the two diagnosis atopic eczema and
respiratory allergy—100 000 permutations were carried out to get an empirical null distribution of the
minP (minimum p-value) statistic from which the corrected p-values could be estimated Two-tailed
p ď 0.05 was considered significant [41]. The statistical analyses were performed using R 2.13.1
(R Foundation for Statistical Computing, Vienna, Austria) [42].
2.8. Ethic Statement
The study was conducted according to the Helsinki II Declaration [43] and was approved by
the local ethical committee in Umeå, Sweden (Dnr 95–49, 09–017 M and 09–110 M). Pregnant women
were recruited in their 18th gestational week. Participation was voluntary and those mothers who
accepted to participate in the study provided written consent forms concerning collection of cord
blood. Thirteen years later, on behalf of the minors, parents of the adolescents provided a new written
consent form and the adolescents themselves approved their participation orally for skin prick tests
and for fatty acid analyses in cord serum as well as in the new serum samples. Participation was
voluntary and the adolescents were free to decide not to participate in further tests and questionnaires
without any stated reason.
3. Results
3.1. Fatty Acid Proportions in Serum Phospholipids
Proportions of PUFAs were analyzed in the phospholipid fraction of infant cord and adolescents’
sera. Table 3 shows median proportions of the nine PUFAs that were analyzed in relation to
polymorphism in this study.
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Table 3. Fatty acid proportions (% of total fatty acids) in serum phospholipids at birth and at 13 years
of age.
Serum Phospholipid Proportion Median
(Intraquartile Range)
Fatty Acid Birth (n = 118) 13 Years of Age (n = 120)
n-6
18:2, linoleic 7.9 (7.2–8.9) 23 (21–26)
20:2, eicosadienoic 0.38 (0.34–0.44) 0.31 (0.26–0.37)
20:3, dihomo-γ-linolenic 5.6 (5.1–6.1) 3.9 (3.2–4.8)
20:4, arachidonic 12 (11–13) 10 (8.4–12)
22:4, adrenic 0.56 (0.48–0.62) 0.36 (0.30–0.44)
22:5, osbond 0.41 (0.32–0.50) 0.20 (0.14–0.30)
n-3
20:5, eicosapentaenoic (EPA) 0.27 (0.20–0.36) 1.1 (0.82–1.4)
22:5, docosapentaenoic (DPA) 0.39 (0.29–0.51) 1.2 (1.1–1.5)
22:6, docosahexaenoic (DHA) 4.4 (3.5–5.0) 4.1 (3.4–4.8)
Proportions of fatty acids were expressed as area percentage of total phospholipid fatty acids,
16–22 carbon long.
3.2. Genotyping
The call rate was above 98% in all four SNPs and they all conformed to Hardy-Weinberg
equilibrium (p > 0.2). The LD between the two FADS SNPs was (r2 = 0.53, D’ = 0.75) and LD between
the two ELOVL SNPs was (r2 = 0.43, D’ = 1.0). The minor allele frequency in non-allergic and allergic
subjects in this study are shown in Table 4.
Table 4. Minor allele frequency in non-allergic and allergic subjects in this study.
Minor Allele Frequency
SNP Major > Minor No Allergy(n = 88)
Atopic Eczema
(n = 41)
Respiratory
Allergy (n = 82)
ELOVL2 gene
rs17606561 G > A 0.27 0.22 0.23
rs2236212 G > C 0.38 0.40 0.47
FADS gene cluster
rs102275 T > C 0.39 0.25 0.39
rs174448 A > G 0.36 0.21 0.40
Minor allele frequency in the 211 subjects that were genotyped in this study.
3.3. Association between Polymorphism in the FADS Gene Cluster and Fatty Acids in Cord Serum
Table 5 shows the association between PUFA proportions measured at birth and polymorphism
in the FADS gene cluster and ELOVL2 gene. The associations that were still significant after correction
for multiple testing are denoted with stars in Table 5 and are mentioned here. Subjects carrying
the minor allele of the two SNPs in the FADS gene cluster, rs102275 and rs174448, had elevated
proportions of the n-6 PUFA pathway substrate dihomo-γ-linolenic acid (20:3 n-6) and decreased
proportions of the product arachidonic acid (20:4 n-6) in cord serum. Accordingly, the ratio of
arachidonic acid over dihomo-γ-linolenic acid (20:4 n-6/20:3 n-6) was significantly associated with
both rs102275 and 174448 (Table 5).
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Table 5. Associations between cord serum proportions of n-6 and n-3 PUFAs (% of total FA) and fatty
acid desaturase (FADS) and elongase (ELOVL) polymorphisms.
FADS FADS ELOVL2 ELOVL2
rs102275 T > C rs174448 A > G rs2236212 G > C rs17606561 G > A
Fatty Acid r p r p r p r p
n-6
18:2, linoleic 0.17 0.14 0.19 0.09 0.03 0.81 0.00 0.97
20:2, eicosadienoic ´0.07 0.44 ´0.05 0.56 ´0.01 0.89 ´0.03 0.75
20:3, dihomo-γ-linolenic 0.50 <0.001 *** 0.35 <0.001 ** ´0.09 0.34 ´0.04 0.66
20:4, arachidonic ´0.36 <0.001 ** ´0.34 <0.001 ** ´0.05 0.62 ´0.19 0.042
22:4, adrenic ´0.25 0.006 ´0.26 0.005 0.09 0.35 ´0.10 0.28
22:5, osbond ´0.16 0.09 ´0.14 0.14 ´0.12 0.20 ´0.18 0.06
20:3/18:2 (FADS2) 0.24 0.033 0.09 0.42 ´0.19 0.09 ´0.08 0.48
20:4/20:3 (FADS1) ´0.54 <0.001 *** ´0.43 <0.001 *** 0.04 0.69 ´0.09 0.32
22:4/20:4 (ELOVL2) 0.02 0.87 ´0.01 0.92 0.15 0.10 0.04 0.66
22:5/22:4 (ELOVL2 and FADS2) ´0.06 0.54 ´0.04 0.63 ´0.19 0.039 ´0.14 0.13
n-3
20:5, eicosapentaenoic (EPA) ´0.20 0.08 ´0.11 0.32 0.02 0.83 ´0.00 0.99
22:5, docosapentaenoic (DPA) ´0.06 0.52 ´0.04 0.65 0.12 0.20 0.00 0.96
22:6, docosahexaenoic (DHA) ´0.15 0.12 ´0.15 0.11 0.02 0.81 ´0.14 0.12
22:5/20:5 (ELOVL2) ´0.06 0.60 ´0.12 0.28 0.06 0.59 0.04 0.71
22:6/22:5 (ELOVL2 and FADS2) 0.01 0.91 0.12 0.19 ´0.19 0.038 ´0.15 0.10
The associations between SNPs and fatty acids were analyzed using linear regression. SNPs were coded
according to minor allele count and analyzed as a numeric variable. Fatty acids were expressed as area
percentage of total phospholipid fatty acids, 16–22 carbon long. Abbreviations: FADS = fatty acid desaturase,
ELOVL = elongation of very long chain fatty acids. Correction for multiple inference was carried out by
permutation for each gene separately and 15 phospholipid variables in cord serum. The associations that
were still significant after corrections are denoted by stars: * Corrected p = pc < 0.05; ** pc < 0.01; *** pc < 0.001.
3.4. Association between Polymorphism in the FADS Gene Cluster and Fatty Acids in Adolescent Serum
Table 6 shows the association between PUFA proportions measured at 13 years of age and
polymorphism in the FADS gene cluster and ELOVL2 gene. The associations that were still significant
after correction for multiple testing are denoted with stars in Table 6 and are mentioned here. Similar
to the findings in cord blood, subjects carrying the minor allele of rs102275 had significantly lower
proportions of arachidonic acid (20:4 n-6) in serum phospholipids at 13 years of age and a reduced
ratio of arachidonic acid over dihomo-γ-linolenic acid (20:4 n-6/20:3 n-6) (Table 6).
Table 6. Associations between 13 years of age serum proportions of n-6 and n-3 PUFAs (% of total FA)
and fatty acid desaturase (FADS) and elongase (ELOVL) polymorphisms.
FADS FADS ELOVL2 ELOVL2
rs102275 T > C rs174448 A > G rs2236212 G > C rs17606561 G > A
Fatty Acids r p r p r p r p
n-6
18:2, linoleic 0.05 0.76 ´0.05 0.76 ´0.26 0.10 ´0.05 0.76
20:2, eicosadienoic 0.18 0.050 0.02 0.85 0.10 0.26 0.12 0.21
20:3, dihomo-γ-linolenic 0.12 0.21 0.11 0.24 ´0.02 0.82 ´0.02 0.80
20:4, arachidonic ´0.36 <0.001 ** ´0.23 0.013 0.03 0.73 0.04 0.64
22:4, adrenic ´0.14 0.13 ´0.06 0.49 0.11 0.26 0.05 0.56
22:5, osbond ´0.04 0.63 0.04 0.70 ´0.01 0.90 ´0.06 0.49
20:3/18:2 (FADS2) 0.02 0.90 0.06 0.69 0.22 0.16 0.06 0.71
20:4/20:3 (FADS1) ´0.42 <0.001 *** ´0.30 0.001 * 0.04 0.69 0.03 0.78
22:4/20:4 (ELOVL2) 0.06 0.50 0.07 0.46 0.10 0.28 0.01 0.95
22:5/22:4 (ELOVL2 and FADS2) 0.02 0.85 0.07 0.43 ´0.15 0.11 ´0.23 0.014
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Table 6. Cont.
FADS FADS ELOVL2 ELOVL2
rs102275 T > C rs174448 A > G rs2236212 G > C rs17606561 G > A
Fatty Acids r p r p r p r p
n-3
20:5, eicosapentaenoic (EPA) ´0.11 0.22 ´0.15 0.09 0.07 0.45 0.05 0.60
22:5, docosapentaenoic (DPA) ´0.12 0.18 ´0.02 0.84 0.15 0.11 0.11 0.22
22:6, docosahexaenoic (DHA) ´0.01 0.92 ´0.02 0.87 0.00 0.99 ´0.02 0.86
22:5/20:5 (ELOVL2) 0.08 0.38 0.20 0.032 0.01 0.90 ´0.04 0.70
22:6/22:5 (ELOVL2 and FADS2) 0.11 0.22 0.03 0.72 ´0.16 0.09 ´0.10 0.28
The associations between SNPs and fatty acids were analyzed using linear regression. SNPs were coded
according to minor allele count and analyzed as a numeric variable. Fatty acids were expressed as area
percentage of total phospholipid fatty acids, 16–22 carbon long. Abbreviations: FADS = fatty acid desaturase,
ELOVL = elongation of very long chain fatty acids. Correction for multiple inference was carried out by
permutation for each gene separately and 15 phospholipid fatty acid variables in adolescent serum. The
associations that were still significant after correction are denoted by stars: * Corrected p = pc < 0.05; ** pc < 0.01;
*** pc < 0.001.
3.5. Association between Polymorphism in the ELOVL2 Gene and Fatty Acids in Cord and Adolescent Serum
Two ELOVL2 SNPs were analyzed, rs2236212 and rs17606561. In general, the ELOVL2 SNPs
were less strongly associated with serum fatty acid composition than were FADS cluster gene SNPs
(Tables 5 and 6). No correlations were significant after correction for multiple testing, but some
were nominally significant. For infant cord serum: rs2236212 was nominally weakly negatively
associated with the 22:5 n-6/22:4 n-6 ratio and to the 22:6 n-3/22:5 n-3 ratio and rs17606561 was
weakly negatively associated to the proportion of arachidonic acid (20:4 n-6) (Table 5). In adolescents,
rs17606561 was nominally negatively associated with the ratio 22:5 n-6/22:4 n-6 (Table 6).
3.6. Association between Polymorphism in FADS and ELOVL Genes and Risk for Atopic Disease
Carriers of one minor allele of the two FADS gene cluster SNPs (rs102275 and rs174448) had
reduced capacity to desaturate n-6 series PUFAs. These minor allele carriers had approximately half
the risk of having atopic eczema at 13 years of age, compared to subjects carrying two major alleles
(Table 7). Adding gender to the model did not affect this risk (data not shown). While the associations
are nonsignificant after correction for four tests, the direction of the association is consistent with the
fatty acids being mediators and thus the use of a one sided test would be justified. No association
between the ELOVL2 gene SNPs and risk for atopic eczema was found. Also, no association was
found between any of the four SNPs and the risk of developing respiratory allergy (Table 7). We have
previously shown that several cord serum phospholipid fatty acids are associated with development
of both atopic eczema and respiratory allergy in these children [33]. If any of the fatty acids that
are associated with eczema were added to the logistic models shown in Table 7, the significance
of rs102275 and rs174448 disappeared (data not shown), suggesting that the FADS polymorphisms
reduced atopic eczema development by reducing the capacity to produce long-chain PUFAs.
Table 7. Association between FADS and ELOVL genes and atopic eczema and respiratory allergy.
Logistic Regression
Atopic Eczema Respiratory Allergy
Gene SNP (Major > Minor) OR p (pc) OR p (pc)
FADS rs102275 (T > C) 0.52 (0.28–0.95) 0.035 (0.104) 1.02 (0.65–1.6) 0.94 (1)
FADS rs174448 (A > G) 0.48 (0.26–0.88) 0.018 (0.055) 1.15 (0.76–1.75) 0.52 (0.9)
ELOVL rs2236212 (G > C) 1.08 (0.64–1.8) 0.78 (1) 1.45 (0.94–2.25) 0.10 (0.3)
ELOVL rs17606561 (G > A) 0.77 (0.41–1.44) 0.41 (0.8) 0.80 (0.48–1.32) 0.37 (0.8)
The association between SNPs and allergy was analyzed with logistic regression. SNPs were coded according
to minor allele count and analyzed as a numeric variable. Abbreviations: OR = odds ratio per minor allele.
Correction for multiple testing was carried out by permutation for each gene separately and for the two
diagnosis atopic eczema and respiratory allergy.
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3.7. Haplotype Analysis
Haplotypes of rs102275-rs174448 were constructed and are shown in Table 8. The LD between
the two FADS SNPs was (r2 = 0.53, D’ = 0.75) and LD between the two ELOVL SNPs was (r2 = 0.43,
D’ = 1.0). While haplotype regression was significant for the same fatty acids as rs102275, when the
SNPs were included in the same model only rs102275 stood out as significant.
Table 8. Haplotypes of rs102275-rs174448 and of rs2236212-rs17606561.
Haplotype Frequency
FADS gene cluster rs102275-rs174448
C–G 0.292
T–G 0.055
C–A 0.072
T–A 0.581
ELOVL2 gene rs2236212-rs17606561
A–C 0.238
G–C 0.185
G–G 0.577
4. Discussion
Both desaturase and elongase enzymes are involved in the endogenous production of long chain
PUFAs (ě 20 carbon atoms) of the n-6 and n-3 series from precursors of 18 carbon atom chain-length.
To our knowledge, this is the first study to compare the effect of polymorphisms in genes encoding
for both these enzymes, the FADS genes and the ELOVL2 gene, on fatty acid profiles at two time
points, at birth and at 13 years of age in the same children. This is also the first study to analyze
the association between allergy development and polymorphism in the ELOVL2 gene. The results
showed that polymorphism in the FADS genes and, nominally, in the ELOVL2 gene were associated
with the proportions of some n-6 PUFAs in serum phospholipids. Thus, minor allele carriers were
found to have lower proportion of the long-chain product in the serum phospholipids and increased
proportions of the substrate. The desaturases and elongases works on both n-3 and n-6 PUFAs, but the
SNPs investigated here were mainly found to affect the n-6 PUFA levels, as previously shown [15,22].
The potential differential effect of polymorphism on PUFA proportions at the two time points
are not assessed. Other factors than polymorphism in the FADS and ELOVL genes influence the
proportions of PUFA differently at birth and at adolescent state, also difference in storage time
between cord serum samples and adolescent serum samples might affect the results of the PUFA
measurements. The PUFA levels in cord blood might be partly affected by the efficiency of the
transport of PUFAs across the placenta from the maternal to the fetal circulation. While the PUFA
levels in adolescence might be more affected by e.g., differences in dietary intake. We have previously
shown that fish intake correlated to proportions of n-3 long chain PUFAs in these subjects at 13 years
of age [36]. In contrast to our findings, a previous study [22] found stronger correlations between
FADS polymorphisms and long chain PUFA proportions in serum at seven years of age than at birth.
Previous studies have revealed that single nucleotide polymorphism (SNPs) in the FADS gene
cluster affect the proportions of PUFA and long chain PUFA in human tissue [7–23]. Polymorphism
in the FADS genes carried by the minority of subjects have generally been associated with enhanced
blood proportions of the n-6 and n-3 substrate fatty acids and decreased proportions of the product
fatty acids, similar to the results in this study. However, the associations between FADS alleles and
cord blood proportions of PUFAs has only been investigated in a single birth-cohort, the ALPSAC
cohort from which two studies derive [15,22]. Steer et al. [22] investigated genetic variation in both
the mother and the child in two FADS2 SNPs, rs1535 and rs174575, in relation to fatty acids at three
time points, i.e., in maternal red blood cells during pregnancy, in cord plasma at birth and in child
plasma obtained at seven years of age. Lattka et al. [15] analyzed associations between 17 additional
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SNPs in the whole FADS gene cluster and cord plasma fatty acid proportions in the same cohort, one
of which, rs174448, was analyzed in our study. In both studies investigating the ALPSAC cohort, the
minor alleles were associated with reduced amounts of the products and enhanced amounts of the
precursors, and stronger associations between FADS SNPs and the n-6 series of PUFAs, than with
the n-3 series of PUFAs [15,22]. Further, similar to our findings, rs174448 was associated with lower
proportions of 20:3 n-6 and higher proportions of 20:4 n-6 and 22:4 n-6 in cord serum phospholipids,
but no effect on n-3 PUFAs [15].
The pathway of endogenous production of long chain n-6 and n-3 PUFAs involves another gene
family, elongases, which elongates the fatty acid chain. In the present study two ELOVL2 SNPs were
analyzed: rs17606561 and rs2236212. Minor allele carriers of rs17606561 had decreased proportions
of arachidonic acid (20:4 n-6) and minor allele carriers of rs2236212 had a lower ratio of DHA over
DPA (22:6 n-3/22:5 n-3) in cord serum. However, none of these associations persisted correction
for multiple testing. Similar results, with increased proportions of DPA and decreased proportions
of DHA in minor allele carriers of rs2236212 were found by Lematire et al. [25] in adults. To our
knowledge no previous studies have evaluated the association between ELOVL2 polymorphism and
fatty acid proportions in cord serum phospholipids.
The SNPs in the present study were chosen to represent all SNPs in the FADS gene cluster
or the ELOVL gene family that have shown significant association to serum phospholipids in two
genome-wide association studies [24,25]. Lematire et al. found that minor allele carriers of rs102275
had increased proportions of α-linolenic acid (18:3 n-3) and decreased docosapentaenoic acid (22:5
n-3, DPA) proportions. Minor allele carriers of rs174448 had increased proportions of α-linolenic
acid, decreased eicosapentaenoic acid (20:5 n-3, EPA) proportions and decreased docosahexaenoic
acid (22:6 n-3, DHA) proportions [25]. We did not replicate the results found by Lematire et al.
regarding n-3 PUFAs since we only found significant associations between n-6 PUFAs and these SNPs.
Demirkan et al. [24] analyzed the genome-wide association to circulating phospholipid concentrations
and found both amounts and proportions of many phospholipids to be associated to FADS1 and
ELOVL2 polymorphism on a genome wide level. Demirkan et al. [24] did not report the fatty acid
composition in the phospholipids and our results are therefore not comparable. A recent Genome
Wide Association Study showed rs102275 and rs174448 to have a genome wide significant association
to a range of long chain fatty acids, e.g., 20:3 n-6 and 20:4 n-6 [23]. This study also found SNPs in the
ELOVL2 gene to be associated with 22:5 n-3 (DPA) [23], however none of the ELOVL SNPs were
analyzed in our study.
Two SNPs in the FADS gene cluster were analyzed here: rs102275 and rs174448. The SNP
rs102275 is situated intergenic downstream of FADS1 and is in strong LD with other SNPs in FADS1
and FADS2 genes. The strongest association of the rs102275 polymorphism was found for the
product/precursor ratio for the ∆-5-desaturase in the n-6 pathway. The other analyzed SNP in
the FADS gene cluster, rs174448, is situated intergenic between FADS2 and FADS3. When the two
FADS SNPs were added together in the linear regression models with fatty acids, only rs102275 was
significant. The same was true when the haplotypes of rs102275-rs174448 were added. This indicates
that the association to rs174448 is just a consequence of the LD with rs102275. These findings are also
in accordance with the findings by Ameur et al. [44] who found two haplotype blocks in the FADS
region, where rs102275 is situated in their LD block 1 that had the strongest association to long chain
PUFAs and rs174448 is in their LD block 2 with weaker association. Additionally, the C and T alleles
of rs102275 corresponds to the haplotypes they denoted A and D respectively in block 1 and our
association pattern with the n-6 PUFAs is in agreement with theirs.
10110
Nutrients 2015, 7, 10100–10115
The subjects in this study were selected based on their allergic manifestation at 13 years of age.
The power of this study may be limited by the relative small population size, however, the prospective
birth cohort design allowed us to select very clear cases with only one allergic manifestations as well
as non-allergic controls that had not been sensitized nor had any allergic symptoms in any of the
follow-ups at 1, 4, 7, or 13 years of age. We aimed for two group of subjects that had allergic symptoms
from one organ only, i.e., atopic eczema or respiratory allergy, since the literature suggests that the
association between PUFAs and allergy may differ in different allergic manifestations [36,45–47].
Here, an association between SNPs in the FADS gene cluster and allergy were found only for subjects
with atopic eczema and not for subjects with respiratory allergy. The minor alleles of rs102275 (C)
and the minor allele of rs174448 (G) were nominally protective against developing atopic eczema.
However, as expected, the significance of rs102275 and rs174448 with atopic eczema disappeared
when any of the five fatty acids that are associated with eczema as well as the SNP are added to
the logistic model, suggesting that the association between the minor FADS allele and protection
from atopic eczema development acts via a reduced capacity to elongate precursor n-6 PUFAs to
arachidonic acid (20:4 n-6).
The association between SNPs in the FADS gene cluster and allergic diseases has been
reported in three German (ECRHS, LISA, GINI) and one Dutch (KOALA) study with inconsistent
results [13,17,48,49]. Schaeffer et al. found that adult minor allele carriers of several SNPs had lower
prevalence of self-reported allergic rhinitis (n = 76) and atopic eczema (n = 49) in the German ECRHS
study [13]. To the contrary, Rzehak et al. that reported results from the two birth cohort studies,
KOALA and LISA, found that minor allele carriers of several SNPs in the FADS gene cluster had
a higher prevalence of parental reported eczema at two years of age (n = 166) [17]. However, the
association between polymorphism in the FADS genes and allergy has also been reported for the
LISA study when the participants were 6 [49] and 10 years old [48], together with subjects from the
GINI study. At these two later ages there were no longer any association between polymorphism
and asthma, bronchitis, eczema or hay fever at 6 years of age [49] or at 10 years of age [48]. Further
studies are needed to confirm the protective effects of the minor allele in FADS genes polymorphism
found on atopic eczema in this study and on atopic eczema and allergic rhinitis in the study by
Schaeffer et al. [13].
We have previously published the association between serum proportions of fatty acids and
allergy in the same subjects [33,36], this paper additionally adds the polymorphisms. We reported
that high proportions of long chain PUFAs at birth, in cord serum, were associated with allergy
development [33]. At 13 years of age, when the allergic disease was manifest, there was no longer
any correlation between atopy and serum PUFA proportions [36], which suggests that the PUFA
milieu is important chiefly during early infancy when the naïve immune system of the infant is
primed as foreign antigens are encountered. The mechanism by which high proportions of long-chain
PUFAs in cord blood increases the risk of allergy development is unknown. Arachidonic acid is a
precursor for prostaglandin E2 (PGE2) that promotes maturation of dendritic cells into a phenotype
that supports Th2 development [50]. Furthermore, PUFAs counteract T cell activation and production
of interferon-gamma; if the immune system is not activated in early infancy because of low microbial
stimulation, or a mileu rich in PUFA, immune maturation might be hampered. Interestingly, the other
allergic phenotype, respiratory allergy, which was also associated with a higher proportion of long
chain PUFAs in cord serum [33] were not associated with having a different genotype. However,
we found the strongest risk of respiratory allergy development to be connected with n-3 PUFAs [33]
and these were obviously not strongly affected by the gene polymorphisms studied here. This might
suggest that n-3 PUFAs in the fetus are derived chiefly from placental transport from the maternal
circulation and are less dependent on synthesis by the fetus, and hence not as strongly associated to
genetic variation in the FADS and ELOVL genes.
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5. Conclusions
In the present study we found polymorphisms in the FADS gene cluster to be associated with
lower proportions in cord serum phospholipids of arachidonic acid and adrenic acid (the products
of the reaction catalyzed by the desaturase enzyme) and higher proportions of dihomo-γ-linolenic
acid (the precursor). The results were similar, but less pronounced in the subjects when investigated
at 13 years of age. We also found that polymorphisms in the FADS gene cluster were nominally
associated with reduced risk of developing atopic eczema. The association between a reduced
capacity to desaturase n-6 PUFAs due to FADS polymorphisms and reduced risk for eczema
development, could indicate a pathogenic role for long-chain PUFAs in allergy development.
Polymorphisms in the ELOVL2 gene were nominally associated with decreased proportions of
arachidonic acid in cord serum and decreased ratio of product over substrate in cord and adolescent
serum, but not to the risk of developing allergic disease.
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